FIELD: medicine.
SUBSTANCE: new derivative of diaminopyrroloquinazolines of formula (I) and their pharmaceutically acceptable salts possess properties of proteintyrosine posphatase PTP1 inhibitors which can be used for treating the diseases mediated by action of the latter, particularly for decreasing glucose content in blood. In formula (I) , A stands for 6-membered aromatic ring, or 5- or 6-membered aromatic ring which contains 1 or 2 heteroatoms chosen from S, N and O; R1 is specified from the group including the following radicals: C1-6alkyl, hydroxyC1-6alkyl, mono- or dihydroxy-substituted C1-6alkyl, phenyl-(C1-6alkyl), benzyloxyC1-6alkyl and phenyl-(C1-6alkoxy)C1-6alkyl; R2 is specified from the group including the following radicals: hydrogen, C1-6alkyl, hydroxyC1-6alkyl, mono- or dihydroxy-substituted C1-6alkyl, phenyl-(C1-6alkyl) and phenyl-(C1-6alkoxy)C1-6alkyl; R3 represents hydrogen or methyl; Ra is specified from the group including the following radicals: hydrogen, C1-6alkyl, C1-6alkoxy, hydroxyC1-6alkyl, mono- or dihydroxy-substituted C1-6alkyl, phenyl(C1-6alkyl), benzyloxyC1-6alkyl or ; R10 represents hydrogen or ; x and y separately stand for integers 0 to 4; Rb and Rc are separately specified from the group including the following radicals: hydrogen, C1-6alkyl, perfluorochemical C1-6alkyl, substituted C1-6alkyl, C1-6alkoxy, phenoxy, halogen, (unsubstituted C1-6alkyl)-(substituted phenyl)-(C1-6alkyl), phenyl-(C1-6alkoxy) or ; R11 represents hydrogen, phenyl or unsubstituted C1-6alkyl; p stands for integer 0 to 1; Rd represents hydrogen, substituted C1-6alkyl or perfluorochemical C1-6alkyl; Re represents hydrogen, halogen, substituted C1-6alkyl and perfluorochemical C1-6alkyl; Rf represents hydrogen or C1-6alkyl; the substitutes found in alkyl groups are independently specified from the following groups: hydroxy, C1-6alkoxy, C1-6alkanoyl; and the substitutes found in substituted phenyl as Rb and Rc, are independently specified from the following groups: C1-6alkyl, C1-6alkoxy, hydroxyC1-6alkyl, hydroxyl, hydroxylC1-6alkoxy, halogen, perfluorC1-6alkyl and C1-6alkanoyl.
EFFECT: improved properties of the derivatives.
29 cl, 2 dwg, 48 ex
Title | Year | Author | Number |
---|---|---|---|
DIAMINOPYRROLO QUINAZOLINES DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | 2004 |
|
RU2345079C2 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
HISTONE DEACETYLASE INHIBITORS | 2014 |
|
RU2673819C2 |
ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2018 |
|
RU2801302C2 |
DERIVATIVES OF PYRAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 1993 |
|
RU2142946C1 |
TRICYCLIC PYRROLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS KINASE INHIBITORS | 2012 |
|
RU2591191C2 |
AMINOQUINAZOLINE COMPOUNDS | 2005 |
|
RU2382034C2 |
COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
Authors
Dates
2009-09-20—Published
2004-05-10—Filed